Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of JNJ-77242113 vs placebo and deucravacitinib in moderate to severe plaque psoriasis
2023-507039-39-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2024
- Modality
- Peptides
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of icotrokinra in plaque psoriasis (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: IGA response at Week 16 and PASI 90 at Week 16. Planned start Mar 2024; status: authorised.
02
Drugs
icotrokinra
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2023-507039-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507039-39-00.